Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active ulcerative colitis: Final results from the Phase 3 U-ACHIEVE Maintenance study
In this medfyle
A previous analysis of 451 patients in U‑ACHIEVE Maintenance found greater efficacy versus placebo after 52 weeks’ maintenance. This new analysis from the full intent-to-treat population confirms the earlier findings, with significantly better results across all endpoints compared to placebo.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This is a summary of an oral session given at the UEG Week 2022 and presented by:
Prof. Severine Vermeire
University Hospital Leuven
Leuven, Belgium
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference summary.
In addition, an expert commentary on the topic has been provided by:
Prof. James Lindsay
Consultant Gastroenterologist, Barts Health NHS Trust
The Royal London Hospital, London
London, UK
Professor of Inflammatory Bowel Disease, Centre for Immunobiology
Blizard Institute, Barts and the London School of Medicine
Queen Mary University of London
London, UK
